

IN THE UNITED STATE PATENT AND TRADEMARK OFFICE

In re the Application of: **Garvey et al**

Application No: **09/516,194**

Group Art Unit: **1626**

Filed: **March 1, 2000**

Examiner: **R. Gerstl**

For: **Nitrosated and Nitrosylated Prostaglandins, Compositions and Methods of Use**

Attorney Docket No: **102258.285**

Assistant Commissioner of Patents  
Washington, DC 20231

**RECEIVED**

OCT 26 2001

TECH CENTER 1600/2900

**AMENDMENT UNDER 37 C.F.R. §1.48 (b)**

The correct inventors were named in the above application. In view of the Restriction Requirement dated May 8, 2001 and the Office Action dated July 24, 2001, in which the Examiner has withdrawn from consideration claims directed to the non-elected species, an amendment is filed concurrently in which claims 9, 18, 32, 41-103 and 107-115 have been canceled without prejudice. In view of the cancellation of the original claims, fewer than all of the currently named inventors are the actual inventors of the invention now being claimed in this application.

Pursuant to 37 C. F. R. §1.48 (b), on behalf of NitroMed, Inc., the assignee of the above application, I respectfully request that Manuel Worcel and Sang William Tam be deleted as inventors of the above application, as their invention is not set forth in the pending claims. NitroMed, Inc. is the assignee of the above application pursuant to an Assignment recorded in the U. S. Patent Office on March 1, 2000, at Reel 010661, Frame 0399, and an Assignment recorded in the U. S. Patent Office on May 5, 2000, at Reel 010846, Frame 0097.


Pursuant to 37 C. F. R. §1.48 (b)(1), I certify that I am authorized to act on behalf of NitroMed, Inc. I respectfully request that the inventorship be corrected by deleting the names of Manuel Worcel and Sang William Tam. I acknowledge that Manuel Worcel's and Sang William Tam's invention is no longer being claimed in the above application.

10/23/2001 09:12:22 00000030 080219 09516194  
01 FC:122 130.00 CH

Amendment under 37 C.F. R. §1.48 (b)  
Application No. 09/516,194

Pursuant to 37 C. F. R. §1.48 (b)(2), the Commissioner is authorized to charge the processing fee of \$130 to Deposit Account No. 08-0219. The Commissioner is authorized to charge any other fees to Deposit Account No. 08-0219 to maintain the pendency of the present application.

Respectfully submitted

A handwritten signature in black ink, appearing to read "L. Gordon Letts", written over a horizontal line.

L. Gordon Letts, Ph. D.  
Senior Vice President Research, Chief Scientific  
Officer  
NitroMed, Inc.  
12 Oak Park Drive  
Bedford, MA 01730

Date: October 22, 2001

1626

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Garvey et al**

Application No. **09/516,194**

Group Art Unit: **1626**

Filed: **March 1, 2000**


Examiner: **R. Gerstl**

For: **Nitrosated and Nitrosylated Prostaglandins, Compositions  
and Methods of Use**

Attorney Docket No: **102258.285**

Assistant Commissioner of Patents  
Washington, DC 20231

**RECEIVED**  
OCT 26 2001  
TECH CENTER 1600/2900




**Transmittal Letter**

Enclosed herewith for filing in the US Patent and Trademark Office is:

1. Amendment under 37 CFR § 1.48(b).
2. Response and Amendment under 37 CFR § 1.111 with Appendixes 1-2.

The Commissioner is authorized to charge the fee of **\$130** for the Amendment under 37 CFR § 1.48(b) to Deposit Account No. 08-0219. The Commissioner is also authorized to charge any other fees or credit any overpayments to Deposit Account No. 08-0219 to maintain the pendency of the present application. The fees charged reflect the small entity status of the present application.

Respectfully submitted,

  
Edward D. Grieff  
Registration No. 38,898

Date: October 24, 2001  
Hale and Dorr LLP  
1455 Pennsylvania Avenue, NW  
Washington, DC 20004  
Phone: 202-942-8400